Zevra Therapeutics (ZVRA) Gains from Investment Securities (2014 - 2025)

Zevra Therapeutics has reported Gains from Investment Securities for 12 years, with the latest figure at $308.9 million in Q4 2025.

• For the quarter ending Q4 2025, Gains from Investment Securities changed N/A year-over-year to $308.9 million; the trailing twelve-month figure through Mar 2026 stood at $308.9 million (up 20035.01% YoY), and the FY2025 full-year result was $310.0 million, up 5108.62% from the prior year.
• Gains from Investment Securities for Q4 2025 stood at $308.9 million, up from -$156.6 million in the prior quarter.
• The five-year high for Gains from Investment Securities was $308.9 million in Q4 2025, with the low at -$156.6 million in Q3 2025.
• Historically, Gains from Investment Securities has averaged $22.2 million across 5 years, with a median of $20000.0 in 2021.
• The largest YoY upside for Gains from Investment Securities was 121293.02% in 2025 against a maximum downside of 54098.97% in 2025.
• Zevra Therapeutics' Gains from Investment Securities stood at -$92000.0 in 2021, then sank by 333.7% to -$399000.0 in 2022, then soared by 11558.9% to $45.7 million in 2023, then plunged by 99.37% to $290000.0 in 2024, then soared by 106407.24% to $308.9 million in 2025.
• The last three Gains from Investment Securities figures came in at $308.9 million (Q4 2025), -$156.6 million (Q3 2025), and $156.6 million (Q2 2025), per Business Quant data.